Terms: = Prostate cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
6 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract] [Full Text] [Related]
3. Immune Checkpoints, Inhibitors and Radionuclides in prostate cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract] [Full Text] [Related]
4. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract] [Full Text] [Related]
5. Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.
La Rocca E; Dispinzieri M; Lozza L; Mariani G; Di Cosimo S; Gennaro M; Valdagni R; De Santis MC
Med Oncol; 2018 Nov; 36(1):4. PubMed ID: 30443687
[TBL] [Abstract] [Full Text] [Related]
6. Preexisting Levels of CD4 T Cells Expressing pd-1 Are Related to Overall Survival in prostate cancer Patients Treated with Ipilimumab.
Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
[TBL] [Abstract] [Full Text] [Related]
